Lu-177-PSMA-617 before Radical Prostatectomy for the Treatment of High Risk Localized Prostate Cancer
This phase II trial tests how well Lu-177-PSMA-617 followed by surgery to remove the entire prostate (radical prostatectomy) works for treating patients with high risk prostate cancer that has not spread to other parts of the body (localized). Lu-177-PSMA-617 is a radioactive drug. It binds to a protein called prostate specific membrane antigen (PSMA), which is found on some prostate tumor cells. Lutetium Lu 177-PSMA builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate. Giving Lu-177-PSMA-617 followed by radical prostatectomy may be effective in treating patients with high risk localized prostate cancer.
Inclusion Criteria
- Patients age 18 or older
- Patients with histologically confirmed adenocarcinoma of the prostate
- Patients with high-risk disease defined as a preoperative prostate biopsy of Gleason Score 8 (GS8) (grade group 4 [GG4]) or higher. Men with evidence of lymph node involvement at or below the bifurcation of the common iliac arteries (cN1) on PET-CT 68Ga-PSMA-11 are eligible
- Pre-operative, pre-treatment PSMA scan with high expression in prostate confirmed by PET/CT 68Ga-PSMA-11 (greater than liver). Patients must not have any other PET fludeoxyglucose (FDG) positive sites outside the prostate
- Patients who are able and willing to undergo surgery
- Patients with a life expectancy of greater than 10 years. Life expectancy can be estimated using any 1 of the following tools: * The Social Security Administration tables: https://www.ssa.gov/OACT/STATS/table4c6.html * The World Health Organization (WHO’s) Life Tables by country: https://apps.who.int/gho/data/view.main.60000?lang=en * The Memorial Sloan Kettering Male Life Expectancy tool: https://www.mskcc.org/nomograms/prostate ** If using a life expectancy table, life expectancy should be adjusted using the clinician’s assessment of overall health as follows: best quartile of health - add 50%; worst quartile of health - subtract 50%; and middle two quartiles of health - no adjustment. See the National Comprehensive Cancer Network (NCCN) Prostate Cancer Guidelines for more information
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Patients who agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agree to refrain from donating sperm, as defined below: * With a female partner of childbearing potential who is not pregnant, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 14 weeks after the final dose of study treatment. Men must refrain from donating sperm during this same period. * With a pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 14 weeks after the final dose of study treatment to avoid potential exposure to the embryo. * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not adequate methods of contraception
- Patients who are able to comply with follow-up visits and treatment plans
- Patients who are able to give informed consent
Exclusion Criteria
- Patients with high risk disease by prostate specific antigen (PSA) > 20 ng/mL or cT3 or higher
- Patients with a prior history of prostate cancer treatment
- Patients with previous treatment with PSMA-targeted radioligand therapy or any of the following within 6 months of enrollment confirmation: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 or hemi-body irradiation
- Patients with distant disease (outside of local lymph nodes)
- Platelet count lower than 100 x 10^3/μl
- White blood cell (WBC) count lower than 4 ×10^3/μl
- Hemoglobin concentration lower than 9 mg/dl
- Albumin concentration lower than 3.5 gr/dl
- Total bilirubin higher than 2gr/dl
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) higher than 2 times the upper limits of normal
- International normalized ratio (INR) higher than 1.5
- Impaired kidney function defined by glomerular filtration rate (GFR) lower than 40 mL/min, or concomitant use of nephrotoxic drugs. Kidney function based on estimated GFR (eGFR) by Modification of Diet in Renal Disease (MDRD) equation: * Normal renal function: participants with eGFR ≥ 90 ml/min * Moderate renal impairment: participants with eGFR ≥ 30 to ≤ 59 ml/min * Severe renal impairment: participants with eGFR ≥ 15 to ≤ 29 ml/min
- Patients with significant comorbidities that would make them poor candidates for surgery
- Patients with evidence of metastatic disease (enlarged lymph nodes, distant metastatic sites, visceral or bone metastases, etc.)
- Patients with a history of radiation or hormone therapy to the prostate
- Patients with a history of bleeding disorders or who are taking anticoagulant therapy
- Patients with active infections or other contraindications for surgery
- Patients who are unable or unwilling to give informed consent
- Patients who are unable to comply with follow-up visits and treatment plans
Additional locations may be listed on ClinicalTrials.gov for NCT06798558.
Locations matching your search criteria
United States
District of Columbia
Washington
New Jersey
Hackensack
PRIMARY OBJECTIVE:
I. To assess immediate oncological responses after 2 cycles of Lutetium Lu 177 vipivotide tetraxetan (Lu-177-prostate specific membrane antigen [PSMA]-617) (PluvictoⓇ) administered at 6-week intervals in patients with high risk localized prostate cancer before undergoing radical prostatectomy.
SECONDARY OBJECTIVES:
I. To assess changes in margin status, T staging and seminal vesicle involvement with Lu-177-PSMA-617 (PluvictoⓇ) in patients with high risk localized prostate cancer.
II. To assess the extent of PSMA-avid disease changes with Lu-177-PSMA-617 (PluvictoⓇ) using 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) scan in patients with high risk localized prostate cancer.
III. To assess the safety of radical prostatectomy performed after 2 cycles of Lu-177-PSMA-617 (PluvictoⓇ) in patients with high risk localized prostate cancer.
IV. To assess quality of life (QoL) and sexual function changes following treatment with Lu-177- PSMA-617 (PluvictoⓇ) and prostatectomy.
V. To evaluate the incidence of biochemical recurrence at 2 years following treatment with Lu-177-PSMA-617 (PluvictoⓇ) and prostatectomy.
EXPLORATORY OBJECTIVES:
I. To identify whether the surgical removal of the prostate is associated with a significant decrease in the number of circulating prostate extracellular vesicles (EVs).
II. To identify whether the surgical removal of the prostate that results in decrease of circulating prostate EVs can be evaluated by the microribonucleic acid (microRNA) expression profiling of residual circulating prostate EVs.
III. To determine whether the treatment of patients with Lu-177-PSMA-617 (Pluvicto®) and the presence of residual disease can be evaluated by detection and microRNA (miRNA) expression profiling of circulating EVs during and following treatment.
OUTLINE:
Patients receive Lu-177-PSMA-617 intravenously (IV) on day 1 of each cycle. Cycles repeat every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Six weeks later, patients undergo radical prostatectomy with pelvic lymph node dissection. Patients also receive 68-Ga-PSMA-11 IV and undergo PET/CT, single photon computed tomography (SPECT)/CT, and blood sample collection throughout the study.
After completion of study treatment, patients are followed every 3 months for 2 years.
Trial PhasePhase II
Trial Typetreatment
Lead OrganizationHackensack University Medical Center
Principal InvestigatorNitin Yerram
- Primary IDPRELUDE
- Secondary IDsNCI-2025-04728, 2024-0079, CAAA617A1US07T, STUDY00008669
- ClinicalTrials.gov IDNCT06798558